Modern BiTEs, such as tarlatamab (DLL3 × CD3) in SCLC [149], pasotuxizumab (PSMA × CD3) in prostate cancer [150], and etevritamab (EGFRvIII × CD3) in glioblastoma [151], have demonstrated antitumor activity and manageable toxicity profiles in early-phase trials. Here, FOLH1 is linked to prostate carcinoma.